3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other hematologic neoplasm
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
3
Neoplasms
2
Hematologic Neoplasms
2
HER2-positive Breast Cancer
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Lymphoproliferative Disorders
1
Lung Neoplasms
1
Gallbladder Neoplasms
1
Colorectal Neoplasms
1
Interventions
Cisplatin
6
Pemetrexed
5
Carboplatin
5
pembrolizumab
4
Paclitaxel
4
Magnetic Resonance Spectroscopy
4
Docetaxel
4
Gemcitabine
3
Dexamethasone
3
dexamethasone acetate
2
dexamethasone 21-phosphate
2
cemiplimab
2
auricularum
2
Specimen Handling
2
Ramucirumab
2
Radiotherapy
2
Leucovorin
2
Erlotinib Hydrochloride
2
Drug Therapy
2
Calcium Dobesilate
2
pertuzumab
1
oblimersen
1
maimendongtang
1
endostar protein
1
cyclopropapyrroloindole
1
cediranib
1
aumolertinib
1
anamorelin
1
Vitamin B 12
1
Vinorelbine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Lung Neoplasms
×
pertuzumab
×
Clear all
NCT05786716
2025-12-02
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled